On May 29, 2019 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, reported that it has achieved a fourth milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda) (Press release, Takeda, MAY 29, 2019, View Source [SID1234536648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the global, strategic, multi-target collaboration and license agreement with Takeda that was announced in October 2016, Crescendo’s proprietary transgenic platform and engineering expertise is used to identify and configure Humabody-based therapeutics against certain targets selected by Takeda.

This is the fourth collaboration milestone achieved by Crescendo and relates to the progression of an immuno-oncology programme where the Humabody lead has demonstrated in vivo anti-tumour activity. This latest milestone follows the early licensing by Takeda of Crescendo’s first oncologytargeted Humabody in November 2018.

Theodora Harold, CEO of Crescendo, commented:

"We are proud to have achieved another technical milestone in our collaboration with Takeda. This provides further validation of Crescendo’s ability to efficiently deliver differentiated Humabody molecules against specific targets outlined by Takeda."